Drug intelligence / Profile preview

TES-5967

Development stage: Preclinical
Lead developer: TES Pharma
Modality: Small Molecules

Overview

TES-5967 is a small molecule modulator of the orphan nuclear receptor COUP-TFII (Chicken Ovalbumin Upstream Promoter-Transcription Factor II), also known as NR2F2. Developed by TES Pharma, the compound is currently in the discovery stage for oncology indications. COUP-TFII is a transcription factor that plays a significant role in metabolic homeostasis, angiogenesis, and tumor development. By modulating COUP-TFII activity, TES-5967 aims to inhibit tumor growth and progression in various cancer types where this receptor is overexpressed or dysregulated.

Targets

NR2F2 (COUP-TFII / NR2F2)

Beyond the preview

Go deeper on TES-5967.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TES-5967.

Explore the full profile